Skip to main
ASMB
ASMB logo

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences Inc is advancing its clinical-stage programs with a focus on providing innovative oral therapeutics for hepatitis B virus and restoring microbiome health, which diversifies its therapeutic portfolio. Positive early clinical data for its candidates, particularly ABI-5366 and ABI-4334, indicates a favorable pharmacokinetic profile that supports less frequent dosing regimens, enhancing patient compliance and potential market appeal. Additionally, anticipated collaboration outcomes with Gilead could generate significant near-term cash flows, bolstering financial stability and reinforcing the investment case for Assembly's future growth prospects.

Bears say

Assembly Biosciences Inc exhibits a negative outlook primarily due to significant risks associated with its clinical development programs, including the potential for failed trial results, unforeseen safety concerns, and delays in project timelines. The uncertainty surrounding the efficacy and safety of the company's investigational drugs, such as ABI-5366, ABI-4334, and ABI-6250, raises questions about their ability to advance toward regulatory approval. Additionally, the company's reliance on its HBV cure program for revenue generation may be jeopardized by these operational challenges and a potential inability to secure sufficient funding.

Assembly Biosciences (ASMB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 8 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Jul 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.